Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.

Fiche publication

Date publication

janvier 2026

Journal

Crohn's & colitis 360

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Jairath V, Hunter Gibble T, Peyrin-Biroulet L, Sands BE, Hirai F, Hibi T, Loftus EV, Cross RK, Protic M, Chan LS, Morris N, Traxler K, Rubin DT

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41908680

Résumé

Mirikizumab is an anti-IL23p19 antibody that has shown efficacy in treating moderately to severely active Crohn's disease in a phase 2 study. We studied mirikizumab's impact on quality of life in these patients.